Patient & Participant Contact

Immutep is passionate about researching and developing new opportunities to increase wellbeing for those patient’s experiencing the detrimental effects of cancer and other autoimmune diseases. Our lead product, eftilagimod alfa (efti or IMP321) is currently under clinical development in four separate clinical studies to determine the safety, tolerability and efficacy of the product.

Participation in Immutep clinical trials is always based on the patient’s own decision. For further information on these immunotherapy clinical trials, please contact your treating physician.